Ocular Therapeutix (OCUL) Non-Current Deffered Revenue (2013 - 2026)
Ocular Therapeutix's quarterly Non-Current Deffered Revenue came in at $14.0 million in Q1 2026, little changed year-on-year from $14.0 million in Q1 2025, and little changed quarter-over-quarter from $14.0 million in Q4 2025.
Ocular Therapeutix has reported Non-Current Deffered Revenue for 13 years, with the latest figure at $14.0 million in Q1 2026.
- For the quarter ending Q1 2026, Non-Current Deffered Revenue changed 0.0% year-over-year to $14.0 million; the trailing twelve-month figure through Mar 2026 stood at $14.0 million (changed 0.0% YoY), and the FY2025 full-year result was $14.0 million, changed 0.0% from the prior year.
- Non-Current Deffered Revenue for Q1 2026 stood at $14.0 million, roughly flat from $14.0 million in the prior quarter.
- The five-year high for Non-Current Deffered Revenue was $14.3 million in Q2 2023, with the low at $13.0 million in Q2 2022.
- Average Non-Current Deffered Revenue over 5 years is $13.8 million, with a median of $14.0 million recorded in 2024.
- Year-over-year, Non-Current Deffered Revenue advanced 12.78% in 2022 and declined 1.78% in 2024.
- Tracing OCUL's Non-Current Deffered Revenue over 5 years: stood at $13.4 million in 2022, then advanced by 5.59% to $14.1 million in 2023, then retreated by 0.96% to $14.0 million in 2024, then changed by 0.0% to $14.0 million in 2025, then changed by 0.0% to $14.0 million in 2026.
- The last three Non-Current Deffered Revenue figures came in at $14.0 million (Q1 2026), $14.0 million (Q4 2025), and $14.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 225.10 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Ocular Therapeutix | 1.99 Bn | 1.99 Bn | 9.46 Mn | 14.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 14.00 Mn |
| Dec 31, 2025 | 14.00 Mn |
| Sep 30, 2025 | 14.00 Mn |
| Jun 30, 2025 | 14.00 Mn |
| Mar 31, 2025 | 14.00 Mn |
| Dec 31, 2024 | 14.00 Mn |
| Sep 30, 2024 | 14.00 Mn |
| Jun 30, 2024 | 14.00 Mn |
| Mar 31, 2024 | 14.07 Mn |
| Dec 31, 2023 | 14.14 Mn |
| Sep 30, 2023 | 14.20 Mn |
| Jun 30, 2023 | 14.25 Mn |
| Mar 31, 2023 | 13.34 Mn |
| Dec 31, 2022 | 13.39 Mn |
| Sep 30, 2022 | 13.53 Mn |
| Jun 30, 2022 | 13.00 Mn |
| Mar 31, 2022 | 13.10 Mn |
| Dec 31, 2021 | 13.00 Mn |
| Sep 30, 2021 | 12.00 Mn |
| Jun 30, 2021 | 12.00 Mn |
| Mar 31, 2021 | 12.00 Mn |
| Dec 31, 2020 | 12.00 Mn |
| Dec 31, 2018 | 3.22 Mn |
| Sep 30, 2018 | 3.27 Mn |
| Jun 30, 2018 | 3.28 Mn |
| Mar 31, 2018 | 3.34 Mn |
| Dec 31, 2017 | 3.39 Mn |
| Sep 30, 2017 | 3.61 Mn |
| Jun 30, 2017 | 3.15 Mn |
| Mar 31, 2017 | 1.32 Mn |
| Dec 31, 2016 | 537,000.00 |
| Sep 30, 2016 | 32,000.00 |
| Jun 30, 2016 | 42,000.00 |
| Mar 31, 2016 | 55,000.00 |
| Dec 31, 2015 | 68,000.00 |
| Sep 30, 2015 | 81,000.00 |
| Jun 30, 2015 | 94,000.00 |
| Mar 31, 2015 | 103,000.00 |
| Dec 31, 2014 | 112,000.00 |
| Sep 30, 2014 | 121,000.00 |
| Jun 30, 2014 | 119,000.00 |
| Dec 31, 2013 | 27,000.00 |